- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Microba Life Sciences Ltd (MAP)
Microba Life Sciences Ltd stock price live, this page displays ASX MAP stock exchange data. View the MAP premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Microba Life Sciences Ltd real time stock price chart below.
What Is the Microba Life Sciences Ltd Stock Price Today?
The Microba Life Sciences Ltd stock price today is 0.09.
What Is the Stock Symbol for Microba Life Sciences Ltd?
The stock symbol for Microba Life Sciences Ltd is ""MAP.""
What Stock Exchange Does Microba Life Sciences Ltd Trade On?
Microba Life Sciences Ltd is listed and trades on the Sydney stock exchange.
Is Microba Life Sciences Ltd a Good Stock to Buy?
Determining whether Microba Life Sciences Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MAP quote. (ISIN: AU0000209868)
What Is the Microba Life Sciences Ltd Stock Price Today?
The Microba Life Sciences Ltd stock price today is 0.09.
What Is the Stock Symbol for Microba Life Sciences Ltd?
The stock symbol for Microba Life Sciences Ltd is ""MAP.""
What Stock Exchange Does Microba Life Sciences Ltd Trade On?
Microba Life Sciences Ltd is listed and trades on the Sydney stock exchange.
Is Microba Life Sciences Ltd a Good Stock to Buy?
Determining whether Microba Life Sciences Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MAP quote. (ISIN: AU0000209868)
Sydney
Currency in AUD
0.09
0.00(0.00%)
Closed·
Fair Value
An estimate of a Microba Life Sciences's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.09
0.09
52 wk Range
0.07
0.30
MAP is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Microba Life Sciences's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.090.09
52 wk Range
0.070.30
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
MAP Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Microba Life Sciences's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
0.21
Upside
+133.33%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy
Microba Life Sciences Ltd Company Profile
Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; MetaXplore that provides a range of diagnostics solution under the Co-Biome brand; research testing services; and data-driven therapeutics platform that develops therapies for ulcerative colitis, and inflammatory bowel and autoimmune diseases, as well as microbiome databank. Microba Life Sciences Limited was incorporated in 2017 and is based in Brisbane, Australia.
Microba Life Sciences Ltd Earnings Call Summary for Q2/2026
- Microba Life Sciences reported 90% year-on-year growth in core test volume with an annualized run rate exceeding 21,300 tests, targeting over 24,000 tests for FY2026.
- Microbiome Explorer now contributes 55% of total revenue, with core testing products growing 129% year-on-year, successfully replacing AUD 1.6 million in legacy product revenue.
- The company is targeting regional break-even in Australia and UK markets while continuing to release new product features and implement AI to enhance operational efficiency.
- Strategic partnerships are accelerating clinical adoption, with executives projecting the market opportunity could ultimately exceed $1 trillion.
- Future catalysts include anticipated results from Microbiotica clinical trials and potential therapeutic asset partnerships to further strengthen growth trajectory.
Last Updated: 03/02/2026, 11:30
Read Full TranscriptCompare MAP to Peers and Sector
Metrics to compare | MAP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMAPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.7x | 16.5x | −0.5x | |
PEG Ratio | −0.12 | −0.02 | 0.00 | |
Price/Book | 1.7x | 1.5x | 2.6x | |
Price / LTM Sales | 3.5x | 1.2x | 3.3x | |
Upside (Analyst Target) | 133.3% | 22.5% | 46.2% | |
Fair Value Upside | Unlock | 22.3% | 6.6% | Unlock |
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 0.21
(+133.33% Upside)
Earnings
Latest Release
Oct 27, 2025
EPS / Forecast
-- / --
Revenue / Forecast
3.60M / --
FAQ
What Stock Exchange Does Microba Life Sciences Trade On?
Microba Life Sciences is listed and trades on the Sydney Stock Exchange.
TEST
AUD
What Is the Stock Symbol for Microba Life Sciences?
The stock symbol for Microba Life Sciences is "MAP."
What Is the Microba Life Sciences Market Cap?
As of today, Microba Life Sciences market cap is 52.98M.
What Is Microba Life Sciences's Earnings Per Share (TTM)?
The Microba Life Sciences EPS (TTM) is -0.03.
When Is the Next Microba Life Sciences Earnings Date?
Microba Life Sciences will release its next earnings report on 03 Mar 2026.
From a Technical Analysis Perspective, Is MAP a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Microba Life Sciences Stock Split?
Microba Life Sciences has split 0 times.
What is the current trading status of Microba Life Sciences (MAP)?
As of 05 Feb 2026, Microba Life Sciences (MAP) is trading at a price of 0.09, with a previous close of 0.09. The stock has fluctuated within a day range of 0.09 to 0.09, while its 52-week range spans from 0.07 to 0.30.
What Is Microba Life Sciences (MAP) Price Target According to Analysts?
The average 12-month price target for Microba Life Sciences is AUD0.21, with a high estimate of AUD0.29 and a low estimate of AUD0.13. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +133.33% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.